ESPR vs RL · rev $332.3M vs P/E 24, rev $8.11B
Esperion Therapeutics Inc (ESPR) versus Ralph Lauren Corp Class A (RL) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Ralph Lauren Corp Class A (RL) is a apparel manufacturing company listed on US.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported RL revenue for 2026-03-28 was $8.11B. Net income was $941.1M. Revenue was up 14.6% from 2025-03-29 to 2026-03-28. RL currently screens at market cap $16.95B and trailing P/E 24.1.
ESPR currently screens at market cap $816.9M. RL currently screens at market cap $16.95B and trailing P/E 24.1.
Not investment advice. Open the ESPR and RL stock pages for the full models.
Not investment advice.